ArticleClinical cancer research : an official journal of the American Association for Cancer Research2023

Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia.

John N Allan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.